Skip to main content

Table 5 Cox proportional-hazards regression: univariate and multivariate analyses

From: A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

A

Univariate Analysis

Multivariate Analysis

VARIABLE

HR (95% CI); p - value

HR (95% CI); p - value

 

Time to Treatment Failure

BMI

≥ 25 vs < 25

0.54 (0.45–0.66); p < 0.0001

0.74 (0.56–0.97); p = 0.0330

 

Progression Free Survival

BMI

≥ 25 vs < 25

0.49 (0.40–0.59); p < 0.0001

0.77 (0.58–1.01); p = 0.0668

 

Overall Survival

BMI

≥ 25 vs < 25

0.38 (0.31–0.48); p < 0.0001

0.59 (0.43–0.81); p = 0.0013

B

Univariate Analysis

Multiavariate Analysis

VARIABLE

HR (95% CI); p - value

HR (95% CI); p - value

 

Time to Treatment Failure

BMI

≥ 25 vs < 25

0.45 (0.35–0.61); p < 0.0001

0.51 (0.32–0.80); p = 0.0037

 

Progression Free Survival

BMI

≥ 25 vs < 25

0.41 (0.31–0.56); p < 0.0001

0.56 (0.35–0.88); p = 0.0132

 

Overall Survival

BMI

≥ 25 vs < 25

0.25 (0.17–0.36); p < 0.0001

0.27 (0.15–0.48); p < 0.0001

  1. (A) male patients (B) female patients. The used covariates (not shown) were: weight (continuous), irAEs of any grade, primary tumors, line of treatment, ECOG-PS, number of metastatic sites
Back to article page